The Open Otorhinolaryngology Journal

2011, 5 : 10-14
Published online 2011 January 28. DOI: 10.2174/1874428101105010010
Publisher ID: TOOTORJ-5-10

Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas

Kevin C. Huoh and Steven J. Wang
U UCSF Dept of Otolaryngology-Head and Neck Surgery, 2233 Post St, Box 1225, San Francisco, CA 94115, USA.

ABSTRACT

Objectives:

Head and neck nonmelanoma cutaneous carcinomas (NMCC) may have poor outcomes, such as metastasis and recurrence. It remains unclear which patients are at increased risk for poor outcomes. We characterize a population of NMCC seen in a head and neck surgical practice. We sought to identify predictors of poor outcome in head and neck NMCC.

Study Design:

A retrospective cohort study of 161 patients with head and neck NMCC who presented to a university based otolaryngology-head and neck surgery practice over a 13 year period was performed. The study group included 127 men and 34 women, age range: 33 - 92 years.

Subjects and Methods: Tumor characteristics of the study population were recorded, and statistical analysis and Kaplan- Meier survival calculations were performed to determine predictors of poor outcomes.

Results:

113 squamous cell carcinomas (SCC) and 48 basal cell carcinomas (BCC) were identified. Among SCC patients, there was a 44% incidence of metastasis and a 47% incidence of recurrence. Among BCC patients, there was a 10% incidence of metastasis and a 50% incidence of recurrence. Twenty percent of SCC patients had a history of immunosuppression. Among SCC patients with immunosuppression, 83% had metastasis or recurrence. Survival for SCC patients with metastatic disease was significantly worse than patients without metastases. The presence of parotid metastases in SCC conferred a survival advantage when compared to other sites of metastases.

Conclusion:

The incidence of poor outcomes in NMCC was higher in our series than reported in the literature. Survival patterns of our study parallel those of similar studies in the literature.

    External link. Please review our privacy policy.